A Phase 2 Study of CIM331 for Atopic Dermatitis Patients
Phase 2
- Conditions
- Atopic Dermatitis
- Registration Number
- JPRN-jRCT2080222334
- Lead Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 264
Inclusion Criteria
Atopic dermatitis patients
Exclusion Criteria
- Serological evidence of hepatitis B virus or hepatitis C virus infection
- Known human immunodeficiency virus infection
- Evidence of tuberculosis (TB) infection
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method pruritis<br>Visual Analogue Scale (VAS)
- Secondary Outcome Measures
Name Time Method Dermatitis<br>Eczema Area and Severity Index (EASI), SCORing Atopic Dermatitis (SCORAD), static Investigator's Global<br>Assessment (sIGA), Body Surface Area of Atopic Dermatitis involvement